Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Michelson

Showing results (11-20 of 89) with videos related to

Pageof 9
Sort By:
Child Neurology Open|May 16, 2017
Acute Postviral Encephalopathy: Pathologic and Radiologic Correlation in an Atypical CaseAdina Achiriloaie, David Michelson, Li Lei, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|February 24, 2005
Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorderJeffrey H Newcorn, Thomas J Spencer, Joseph Biederman, et al.
The International Journal of Neuropsychopharmacology|March 22, 2012
Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorderDavid Michelson, Richard Hargreaves, Robert Alexander, et al.
Current Alzheimer Research|January 26, 2012
Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of ADMichael Egan, Roy Yaari, Lian Liu, et al.
The Journal of Clinical Psychiatry|March 16, 2005
Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysisLenard A Adler, Thomas J Spencer, Denái R Milton, et al.
Journal of Attention Disorders|May 2, 2008
Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year studyLenard A Adler, Thomas J Spencer, David W Williams, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|January 24, 2007
CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHDDavid Michelson, Holly A Read, Dustin D Ruff, et al.
The Clinical Journal of Pain|April 28, 2017
Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With FilorexantW Joseph Herring, Joy Y Ge, Saheeda Jackson, et al.
Journal of Child and Adolescent Psychopharmacology|September 30, 2005
Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorderStephen V Faraone, Joseph Biederman, Thomas Spencer, et al.
Neurology|October 14, 2018
Evidence in focus: Nusinersen use in spinal muscular atrophy [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of NeurologyDavid Michelson, Emma Ciafaloni, Stephen Ashwal, et al.
Pageof 9

Showing results (11-20 of 89) with videos related to

Sort By:
Pageof 9
Child Neurology Open|May 16, 2017
Acute Postviral Encephalopathy: Pathologic and Radiologic Correlation in an Atypical CaseAdina Achiriloaie, David Michelson, Li Lei, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|February 24, 2005
Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorderJeffrey H Newcorn, Thomas J Spencer, Joseph Biederman, et al.
The International Journal of Neuropsychopharmacology|March 22, 2012
Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorderDavid Michelson, Richard Hargreaves, Robert Alexander, et al.
Current Alzheimer Research|January 26, 2012
Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of ADMichael Egan, Roy Yaari, Lian Liu, et al.
The Journal of Clinical Psychiatry|March 16, 2005
Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysisLenard A Adler, Thomas J Spencer, Denái R Milton, et al.
Journal of Attention Disorders|May 2, 2008
Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year studyLenard A Adler, Thomas J Spencer, David W Williams, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|January 24, 2007
CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHDDavid Michelson, Holly A Read, Dustin D Ruff, et al.
The Clinical Journal of Pain|April 28, 2017
Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With FilorexantW Joseph Herring, Joy Y Ge, Saheeda Jackson, et al.
Journal of Child and Adolescent Psychopharmacology|September 30, 2005
Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorderStephen V Faraone, Joseph Biederman, Thomas Spencer, et al.
Neurology|October 14, 2018
Evidence in focus: Nusinersen use in spinal muscular atrophy [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of NeurologyDavid Michelson, Emma Ciafaloni, Stephen Ashwal, et al.
Pageof 9